Lilly pulls COVID-19 treatment from EU review while U.S. stocks up

Eli Lilly has retracted a request for European Union approval of its antibody-based treatment for COVID-19, citing a lack of demand from EU member states as the bloc focuses on other suppliers. The European Medicines Agency (EMA) said on Tuesday it had ended its rolling review of a cocktail of two monoclonal antibodies known as etesevimab and bamlanivimab after the U.S.-based drugmaker withdrew from the process.